Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Equivalents (2016 - 2025)

Voyager Therapeutics' Cash & Equivalents history spans 11 years, with the latest figure at $65.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 8.5% year-over-year to $65.3 million; the TTM value through Dec 2025 reached $65.3 million, down 8.5%, while the annual FY2025 figure was $65.3 million, 8.5% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $65.3 million at Voyager Therapeutics, up from $43.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $268.3 million in Q1 2023 and bottomed at $43.9 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $105.2 million (2021), against an average of $114.9 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 103.47% in 2023 before it crashed 68.84% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $117.4 million in 2021, then decreased by 15.73% to $99.0 million in 2022, then crashed by 30.47% to $68.8 million in 2023, then rose by 3.73% to $71.4 million in 2024, then dropped by 8.5% to $65.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Cash & Equivalents are $65.3 million (Q4 2025), $43.9 million (Q2 2025), and $74.8 million (Q1 2025).